Sutro Biopharma (STRO)CEO bought ~$10K

~$10K

Approx. value · 13K sh @ $0.8009

123K

Holds after · shares reported

Traded

Oct 15, 2025

Filed

Oct 16, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 29, 2025Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“On September 29, 2025, Sutro Biopharma, Inc. (the “Company”) announced further organizational restructuring to prioritize the advancement of its three preclinical ADC programs and its research and development collaborations.”
2. Oct 15, 2025 · this disclosureInsider · 4 insiders in a week, a first since 2018CEO purchased ~$10K of STRO shares in the open market

What came next

1. Oct 15, 2025Insider · 3 peopleInsiders: 3 purchases (~$70K)
2. Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
3. Dec 1, 2025Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item)
4. Feb 9, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Sutro Biopharma

For Sutro Biopharma, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STRO page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Sutro Biopharma

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its STRO page.